Management of bleomycin lung toxicity is frequently difficult, though steroids are widely recommended and evidence supporting their role comes from both animal studies6 and clinical reports on a few patients.5
Less settled, however, is the value of these agents in advanced bleomycin lung toxicity. Samuels and coworkers7 described a series of five such patients, all of whom received prednisolone in doses of 60-100 mg daily. All five died of acute respiratory failure despite this treatment. Gilson and Sahn8 reported a patient with bleomycin lung toxicity who developed the adult respiratory distress syndrome after surgery and ultimately responded to a combination of antibiotics and methylprednisolone 500 mg a day. Recently Hartmann and colleagues9 also described a patient with life threatening bleomycin lung toxicity successfully treated with methylprednisolone 1 g daily. Our case, taken in conjunction with these, suggests that severe bleomycin lung toxicity may be largely reversible provided that the treatment regimen incorporates corticosteroids in very high doses that are tapered gradually. We elected to use azathioprine in addition because of its immunosuppressive and known steroid sparing effects.
We believe that all patients with bleomycin lung toxicity should receive a trial of corticosteroids. The dose used should depend on the severity of the pneumonitis. Bronchoscopy showed no abnormality.
Owing to spread of adenocarcinoma within and beyond the abdomen, surgical treatment was not indicated and he was treated with three courses of doxorubicin (Adriamycin), vincristine, cyclophosphamide, and 5-fluorouracil, but these had little effect. Thereafter the patient remained in good general condition for several months, during which he was working, though he tired more easily after hard physical work.
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